Thera-SAbDab

ECULIZUMAB

>   Structural Summary
TherapeuticEculizumab
TargetC5
Heavy ChainQVQLVQSGAEVKKPGASVKVSCKASGYIFSNYWIQWVRQAPGQGLEWMGEILPGSGSTEYTENFKDRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARYFFGSSPNWYFDVWGQGTLVTVSS
Light ChainDIQMTQSPSSLSASVGDRVTITCGASENIYGALNWYQQKPGKAPKLLIYGATNLADGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQNVLNTPLTFGQGTKVEIK
100% seqID Fv Structure5i5k [Fvs: HL, XY]
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG2
Highest Clinical Trial (August '22)Approved
Estimated Status (August '22)Active
Recorded Developmental TechnologyGS Gene Expression System
INN Year Proposed2002
INN Year Recommended2003
Companies InvolvedAlexion Pharmaceuticals, Brigham and Womens Hospital, Chiba University, Handok Inc
Conditions ApprovedNeuromyelitis optica, Haemolytic uraemic syndrome, Myasthenia gravis, Paroxysmal nocturnal haemoglobinuria
Conditions ActiveDelayed graft function, Guillain-Barre syndrome, Renal transplant rejection, COVID-19
Conditions DiscontinuedAntiphospholipid syndrome, Heart transplant rejection, Adult respiratory distress syndrome, Age-related macular degeneration, Allergic asthma, Autoimmune haemolytic anaemia, Bullous pemphigoid, Dermatomyositis, Glomerulonephritis, Idiopathic thrombocytopenic purpura, Lupus nephritis, Membranous glomerulonephritis, Motor neuron disease, Psoriasis, Rheumatoid arthritis, Systemic lupus erythematosus
Notes

SAbDab papers

Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]

Dunbar, J., Krawczyk, K. et al. (2014) SAbDab: the Structural Antibody Database. Nucleic Acids Res. 42(D1):D1140-D1146 [link]

Thera-SAbDab paper

Raybould, M.I.J., Marks, C. et al (2020) Thera-SAbDab: the Therapeutic Structural Antibody Database. Nucleic Acids Res. 48(D1):D383-D388. [link]

Our privacy policy